Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Oct 23, 2026
Reporting period
Not applicable
Filed with the SEC
Oct 27, 2026
DirectorGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001193125-26-434468
Filed / recorded
Oct 27, 2026, 9:21 PM UTC
Added to OQRO
Oct 27, 2026, 9:22 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Bolt Biotherapeutics, Inc.
Issuer CIK
1641281
Ticker
BOLT
Reporting person
Sheila Gujrathi
Relationship
Director, Officer
Officer title
Chief Strategy Officer
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Oct 23, 2026
Transaction code
A
Shares / units
72,766
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
72,766
Ownership form
Direct
Amendment
No
Footnotes from the filing
Received in exchange for shares of common stock of Prana Therapies, Inc. ("Prana") pursuant to the Agreement and Plan of Merger dated October 23, 2026 (the "Merger Agreement") by and among the Issuer, Prana, Prince Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("Merger Sub I"), Prince Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer ("Merger Sub II"). Each outstanding share of Prana common stock was converted into the right to receive 1.6413 shares of the Issuer's common stock or common-stock equivalents, consisting of Issuer's common stock and Series D Convertible Preferred Stock ("Series D Preferred") convertible at a rate of 1,000 shares of Issuer's common stock per share of Series D Preferred. No cash purchase price was paid for the Series D Preferred received as merger consideration.
Upon closing of the merger on October 23, 2026, Prana shares held directly by the Reporting Person converted into 72,766 shares of Issuer's common stock and 2,763.833 shares of Series D Preferred. Prana shares held by SilverArc Private Fund I, L.P. converted into 13,055 shares of Issuer's common stock and 495.874 shares of Series D Preferred. The 495.874 shares of Series D Preferred constitute merger consideration
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
